Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression

Dendritic cell (DC) based anti-cancer immunotherapy is well tolerated in patients with advanced cancers. However, the clinical responses seen after adoptive DC therapy have been suboptimal. Several factors including scarce DC numbers in tumors and immunosuppressive tumor microenvironments contribute...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Vivek, Kim, Young, Lee, Min-Cheol, Lee, Jae-Tae, Cho, Sunghoon, Park, In-Kyu, Min, Jung Joon, Lee, Je Jung, Lee, Shee Eun, Rhee, Joon Haeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129979/
https://www.ncbi.nlm.nih.gov/pubmed/27223090
http://dx.doi.org/10.18632/oncotarget.9529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129979/
https://www.ncbi.nlm.nih.gov/pubmed/27223090
http://dx.doi.org/10.18632/oncotarget.9529

Ejemplares similares